ERBB2 and cholangiocarcinoma: Here, we show in a metastatic cholangiocarcinoma with <i>ERBB2</i> amplification identified on liquid biopsy (circulating tumor DNA (ctDNA) testing), a dramatic response to now over 12 months of dual-anti-HER2 therapy.